ID: MRFR/LS/5312-HCR | February 2021 | Region: Global | 100 pages
$1.99 billion
13.2%
North America
2022-2030
Mycoplasma Testing Market is expected to grow significantly over the forecast period. It is anticipated that the mycoplasma testing market held a market value of USD 514 million in 2017 and is projected to grow at a CAGR of 11.6% over the forecast period. Mycoplasma testing used to detect contamination in given biologic sample.
The factors such as Increasing R&D expense and new product launches are expected to propel the growth of the mycoplasma testing market. However, available of alternative traditional method hamper the mycoplasma testing market growth over the forecast period.
Key players:
Charles River Laboratories, Inc., Merck KGaA, Lonza Group Ltd, Roche Diagnostics, SGS S.A., American Type Culture Collection, Invivogen, Wuxi Apptec, Thermo Fisher Scientific Inc., Promocell GmbH are some of the key players in the mycoplasma testing market.
Market Segmentation:
The mycoplasma testing market has been segmented into product, Technique, and application.
Based on product, market segmented into kits & reagents, instruments, and services. The kits & reagents segment is expected to account for the largest share segment of the market in 2017.
Based on Technique, market segmented into DNA Stain, Enzyme-based, PCR, ELISA, Direct Assay, Indirect Assay, Others.
Based on application, market segmented into cell line and cell therapy testing, virus testing, row material testing, lot release testing, and others.
Based on end user, market segmented into pharmaceutical and biological manufacturing, contract research organizations, cell banks, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The mycoplasma testing market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European mycoplasma testing market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The mycoplasma testing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The mycoplasma testing market in the Middle East & Africa has been segmented into the Middle East and Africa.
Global Mycoplasma Testing Market Share (%), by Region, 2017
Source: Annual Reports and Sec filings
Regional Market Summary
Geographically, the Americas is anticipated to dominate the mycoplasma testing market owing to a well-established player and increasing R&D expenses.
Europe is expected to hold the second largest position in the mycoplasma testing market. The market growth in this region is attributed to the growth in pharmaceutical and medical device industry.
The mycoplasma testing market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the increasing adoption of these products.
The Middle East & Africa has the least share of the market.
By Product
By Technique
By Application
By End User
By Region
The report for Mycoplasma Testing Market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
Intended Audience
Report Attribute/Metric | Details |
---|---|
Market Size | 2027: Significant Value |
CAGR | 11.6% (2018-2023) |
Base Year | 2019 |
Forecast Period | 2020-2027 |
Historical Data | 2018 |
Forecast Units | Value (USD Million) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Product, Technique, and Application |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | Charles River Laboratories, Inc., Merck KGaA, Lonza Group Ltd, Roche Diagnostics, SGS S.A., American Type Culture Collection, Invivogen, Wuxi Apptec, Thermo Fisher Scientific Inc., Promocell GmbH |
Key Market Opportunities | Increasing R&D expense and new product launches |
Key Market Drivers | Growing concerns over cell culture contamination |
Frequently Asked Questions (FAQ) :
The mycoplasma testing market is projected to grow at an 11.6% CAGR during the forecast period.
The Americas is projected to command the largest share in the mycoplasma testing market.
It is widely used in lot release testing, virus testing, and others.
New product launches and increasing R&D expenditure is adding market growth.
Availability of alternatives may limit market growth.